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Stifling Scientific Progress: The District Court’s Decision in Myriad
by Seth R. Ogden*
I. Introduction
The human genome contains approximately
23,000 protein-coding genes.1 Approximately twenty
percent of these human genes are patented, with
some genes being patented as many as twenty times.2
On May 12, 2009, the Association for Molecular
Pathology (“AMP”) and nineteen other plaintiffs,
including healthcare associations and individual doctors,
researchers, and patients, filed a lawsuit against the United
States Patent Office (“USPTO”), Myriad Genetics
(“Myriad”) and ten other individual defendants in their
capacity as Directors of the University of Utah Research
Foundation challenging the validity of Myriad’s gene
patents.3 Myriad holds, through either assignment or
exclusive license, a number of domestic and international
patents covering isolated DNA molecules encoding
the BRCA1 and BRCA2 (“BRCA1/2”) mutations that
cause an increased risk for the development of breast
and ovarian cancer and diagnostic methods using
these isolated DNA molecules to identify a patient’s
predisposition to the development of familial breast
cancer.4 In its complaint, AMP alleged that the patent
claims were invalid under Article 1, Section 8, clause 8
of the United States Constitution and 35 U.S.C. § 101
“[b]ecause human genes are products of nature, laws of
nature and/or natural phenomena, and abstract ideas or
basic human knowledge or thought.”5 Similarly, AMP
further asserted that the claims were unconstitutional
under the First and Fourteenth Amendments to the
United States Constitution, as they represent patents
* Seth R. Ogden, BA in Biology, University of Virginia
(2003). PhD in Cancer Biology, Vanderbilt University (2009). JD,
American University Washington College of Law (expected 2012).
USPTO registration number 65,168.
1. International Human Genome Sequencing Consortium,
Finishing the Euchromatic Sequence of the Human Genome, 431
Nature 931, 942 (2004).
2. Kyle Jensen and Fiona Murray, Intellectual Property
Landscape of the Human Genome, 310 Sci. 239, (2005).
3. Complaint at ¶ 27-29, Ass’n for Molecular Pathology v.
U.S. Patent & Trademark Office, 702 F.Supp.2d 181 (S.D.N.Y.
May 12, 2009) (No. 09CV04515), 2009 WL 1343027 [hereinafter
AMP Complaint].
4. Id. at ¶ 31. The challenged patents include US 5,747, 282;
US 5,837,492; US 5,693,473; US 5,709,999; US 5,710,001; US
5,753,441; and US 6,033,857.
5. Id. at ¶ 102.

on abstract ideas or basic human knowledge and/or
thought.6
On March 29, 2010, Judge Robert Sweet of the
United States District Court for the Southern District
of New York granted the plaintiffs’ motion for summary
judgment, holding the patents related to BRCA1/2
invalid.7 Judge Sweet’s resolution of the motion was
“based upon long recognized principles of molecular
biology and genetics: DNA represents the physical
embodiment of biological information, distinct in its
essential characteristics from any other chemical found
in nature.”8 Therefore, Judge Sweet concluded that the
isolated DNA containing sequences found in nature was
unpatentable subject matter under 35 U.S.C. § 101.9
He further concluded that the claimed comparisons
of DNA involved in the diagnostic methods were
simply abstract mental processes, also rendering them
unpatentable under 35 U.S.C. § 101.10 Though
providing no comfort for Myriad, Judge Sweet granted
the USPTO’s motion for summary judgment dismissing
the constitutional claims, invoking the doctrine of
constitutional avoidance.11 Not surprisingly, Myriad
filed a Notice of Appeal to the Court of Appeals for the
Federal Circuit on June 16, 2010.12 Oral arguments
were heard on April 4, 2011.13
Although the district court’s decision’s
applicability is limited to the patents in the instant case,
if upheld by the Federal Circuit, the decision would
have far-reaching implications for human gene patents
currently in force and the future of the biotechnology
industry, both domestically and abroad. Therefore,
this paper seeks to address the legal and policy issues
6. Id. at ¶ 103.
7. Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office, 702 F. Supp. 2d 181, 232, 237 (S.D.N.Y. Mar. 29, 2010).
8. Id. at 185.
9. Id.
10. Id.
11. Id. at 237-38.
12. Notice of Appeal to the Federal Circuit, Association
for Molecular Pathology v. U.S. Patent & Trademark Office, 702
F.Supp.2d 181 (S.D.N.Y. June 16, 2010), No. 09 Civ. 4515 (Fed.
Cir. June 1, 2010).
13. U.S. Court of Appeals for the Federal Circuit, Oral
Argument Recordings, http://www.cafc.uscourts.gov/oral-argumentrecordings/search/audio.html.
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concerning human gene patents in view of the current
decision in Association for Molecular Pathology v. United
States Patent & Trademark Office (hereinafter “Myriad”)
with a view to related cases involving Myriad’s patenting
of isolated DNA molecules encoding BRCA1/2 in the
United States and European forums.
II. Background
A. DNA and Genes – The Information That Life
Depends On
Watson and Crick revolutionized genetic
research in 1953 with their determination of the structure
of deoxyribonucleic acid (“DNA”) and the elucidation of
the implications for such a structure in genetic research.14
DNA exists in nature as linear sequences of nucleotides
(chemical units known as adenine, thymine, guanine,
and cytosine) that are packaged into chromosomes. Each
chromosome contains hundreds of genes, occurring one
after the other as discrete lengths of sequence within
the linear DNA. The order of the nucleotide sequences
within a gene determines the functioning of that gene,
and the characteristics of individual genes collectively
contribute to the genetic traits a person receives.
How does the nucleotide sequence determine
the functioning of a gene? Crick articulated this process
within the framework of what is known as the central
dogma of molecular biology.15 The central dogma
outlines the process by which genes are expressed; in
other words, it describes the mechanism by which the
genetic instructions contained in the nucleotide sequence
of a gene effectuate a function within a cell. Essentially,
DNA is copied repeatedly into a similar form known
as mRNA (transcription), and these numerous copies
of mRNA are turned into protein (translation). These
proteins then interact to carry out a host of functions
within the cell. A simple analogy illustrates the concept:
A person reads instructions (“DNA”) for how to put
a table together, and that person’s brain processes the
information (“transcription”) into a signal (“mRNA”);
that person’s brain then sends out that signal (“mRNA”)
telling their body to carry out the processed instructions
from the brain to put the table (“proteins”) together
14. See Miri Yoon, Gene Patenting Debate: The Meaning of
Myriad, 9 J. Marshall Rev. Int. Prop. L. 953, 954 (2010); see
also James. D. Watson & Francis H. Crick, Molecular Structure
of Nucleic Acid: A Structure for Deoxyribose Nucleic Acid, 171
Nature 737 (1953); James D. Watson & Francis H. Crick, Genetic
Implications of the Structure of Deoxyribonucleic Acid, 171 Nature
964 (1953).
15. See Francis Crick, On Protein Synthesis, Symp. Soc. Exp.
Biol. XII 139 (1958) (presenting a new theory of how genes affect
protein expression and function).
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(“translation”).
Importantly, alterations in the nucleotide
sequences, called mutations, can occur, principally by
either faulty repair of DNA damage or imperfect copying
of DNA when it is passed on to new cells. Many of
these mutations are silent, resulting in no perceptible
consequences. However, certain specific mutations can
increase a person’s risk for the development of a variety of
serious diseases, including cancer.16 Accordingly, certain
mutations of the “breast cancer 1, early onset” and
“breast cancer 2, early onset” (BRCA1/2) genes lead to
increased risk of breast and ovarian cancer. The average
woman in the United States, without such a mutation,
has about a 12% chance of developing breast cancer
in her lifetime, but carriage of an abnormal BRCA1 or
BRCA2 gene augments this to about an 80% chance.17
With regard to ovarian cancer, the average woman has
an approximately 1.4% chance of developing ovarian
cancer, but for a woman with a BRCA1 or BRCA2
mutation that risk increases to 15% to 40%.18
Because an increased risk for breast or ovarian
cancer has many implications for an individual’s choice
of lifestyle and preventative care, the scientific and
healthcare communities have begun to intensify research
into genetic testing to facilitate early identification
of BRCA1/2 mutations in patients. Genetic testing
for mutations within an individual’s DNA sequence
is carried out by one of a number of methodologies
collectively known as gene sequencing, which allows
determinations of the exact order of nucleotides within
a strand of linear DNA.19 Essentially, fluorescent tags
of four distinct colors corresponding to each of the four
nucleotides (adenine, guanine, cytosine, and thymine)
16. See Marisa Noelle Pins, Impeding Access to Quality Patient
Care and Patient Rights: How Myriad Genetics’ Gene Patents Are
Unknowingly Killing Cancer Patients and How to Calm the Ripple
Effect, 17 J. Intell. Prop. L. 377, 384 (2010) (noting that some
inherited mutations may increase a “person’s risk for a variety of
diseases, while others are innocuous”).
17. Cancer Risk and Abnormal Breast Cancer Genes,
Breastcancer.org, http://www.breastcancer.org/risk/genetic/
bcrisk_abnrml_genes.jsp (last visited Oct. 22, 2010). It is
important to note that hundreds of potential mutations have been
identified in BRCA1/2 genes, each one carrying with it a different
level of risk of the development of breast and ovarian cancer.
These percentages simply quantify overall risk for according to the
frequency of each distinct mutation in the female population of the
United States.
18. BRCA1 and BRCA2: Cancer Risk and Genetic Testing,
National Cancer Institute, http://www.cancer.gov/cancertopics/
factsheet/risk/brca#r4 (last visited March 7, 2010).
19. A Brief Guide to Genomics, Nat’l Human Genome
Research Inst., http://www.genome.gov/18016863 (last visited
Oct. 22, 2010).
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are allowed to bind to the DNA.20 These fluorescent
tags are identified by a detector, which provides the
information to a computer in order to reconstruct the
entire gene sequence.21
In order to perform gene sequencing, the
specific gene to be sequenced is purified and isolated
from the individual’s body prior to the introduction
of the fluorescent tags.22 The term “purified” implies
isolation from the gene’s natural state,23 whereas the term
“isolation” implies removal from the body and separation
from the surrounding cellular material.24 This purified
and isolated DNA molecule that encodes such a gene
may therefore be the same in sequence as the naturally
occurring gene, albeit with an altered chemical structure
due to the removal of associated cellular products that
facilitate packaging of the DNA into a chromosome.
Under the current USPTO policy, such a purified and
isolated DNA molecule is patent eligible.25
B. Patenting of Genes and Other Biological
Materials in the United States
1. Development of United States Case Law
The United States Constitution gives Congress
the power “[t]o promote the Progress of Science and
useful Arts, by securing for limited Times to…Inventors
the exclusive Right to their respective…Discoveries.”26
Under this authority, Congress enacted the first Patent
Act in 179027 and the most recently revised Act in 1952.28
35 U.S.C. §101 describes patentable subject matter as
“any new and useful process, machine, manufacture
or composition of matter.”29 Famously, in Diamond v.
20. Id.
21. Id.
22. Pins, supra note 16.
23. See Pins supra note 16 (citing United States Patent &
Trademark Office, Utility Examination Guidelines, 66 Fed. Reg.
1092, 1093 (Jan. 5, 2001)).
24. See id. (citing Plaintiff’s Memorandum of Law in Support
of Motion for Summary Judgment at 2, Ass’n for Molecular
Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515,
2009 WL 3269113 (S.D.N.Y. Aug. 26, 2009).
25. See USPTO, Utility Examination Guidelines, 66
Fed. Reg. 1092, 1093 (Jan. 5, 2001) [hereinafter Examination
Guidelines] (stating that “an inventor’s discovery of a gene can be
the basis for a patent on the genetic composition isolated from its
natural state and processed through purifying steps that separate the
gene from other molecules naturally associated with it.”).
26. U.S. Const. art. I, § 8, cl. 8.
27. An Act to Promote the Progress of Useful Arts, 1 Stat. 109
(1790).
28. Act of 1952, 66 Stat. 792 (1952) (codified as amended at
35 U.S.C. § 101).
29. 35 U.S.C. § 101 (codification of the amended Patent Act
of 1952).

Chakrabarty, the Supreme Court broadly construed such
statutory subject matter “to include anything under the
sun that is made by man,”30 but went on to hold that
“laws of nature, physical phenomena, and abstract ideas”
are excluded from patent-eligible subject matter.31
Under early cases, purified natural products
were generally held to be unpatentable. It is important
to note that despite its conclusions of patent-ineligibility,
the Supreme Court did not appear to rely on the fact that
the subject matter was a product of nature,32 but rather a
lack of novelty33 evidenced by an inability to distinguish
between the natural and purified/synthetic compositions.
In American Wood-Paper Co. v. Fibre Disintegrating Co.,
the court invalidated a patent for extracted wood pulp
because it found the purified product to be the same as
the natural product.34 Similarly, in Cochrane v. Badische
Anilin & Soda Fabrik,35 the court held that a synthetic
dye was not a new composition because it had the same
chemical makeup as the natural dye.36
However, this line of reasoning was challenged
in a line of cases holding that isolation and purification
may alter a composition of matter so as to render it
patent-eligible. Within the chemical context, the court
in Union Carbide Co. v. American Carbide Co.37 found
that a crystalline product described in the application was
different from an amorphous product found in the prior
art due to physical properties that made it better suited
for commercial use in gas generators.38 Similarly, in
Kuehmsted v. Farbenfabriken of Elberfeld Co.,39 the court
upheld a patent for a form of aspirin (acetyl salicylic acid)
purified by a process resulting in an increased therapeutic
effect compared to aspirin purified by previous methods.40
The court noted that “though the difference . . . be one
30. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980)
(quoting S. Rep. No. 1979, 82d Cong., 2d Sess., 5 (1952) and H.R.
Rep. No. 1923, 82d Cong., 2d. Sess., 6 (1952)).
31. Id. at 309 (citing Parker v. Flook, 437 U.S. 584
(1978);Gottschalk v. Benson, 409 U.S. 63, 67, (1972); Funk Brothers
Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130, (1948); O’Reilly
v. Morse, 56 U.S. 62, 112-121, (1854); Le Roy v. Tatham, 55 U.S.
156, 175 (1853)).
32. See Yoon, supra note 14 at 962.
33. The use of the term “novelty” here refers to the inclusion
of the term “new” in the 35 U.S.C. § 101 of patentable subject
matter as contrasted with the statutory bar relating to novelty set
out in 35 U.S.C. § 102.
34. American Wood-Paper Co. v. Fibre Disintegrating Co., 90
U.S. 566, 596 (1874); Pins, supra note 16 at 388.
35. 111 U.S. 293 (1884).
36. Id. at 311.; see also Pins, supra note 16, at 388.
37. 181 F. 104 (2d Cir. 1910).
38. Id. at 107.
39. 179 F. 701 (7th Cir. 1910).
40. Id. at 705.
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of purification only—strictly marking the line, however,
where the one is therapeutically available and the others
were therapeutically unavailable—patentability would
follow.”41 This logic formed the basis for one of the most
notable cases examining the patentability of biological
materials, Parke-Davis & Co. v. H. K. Mulford Co.42 In
that decision, Judge Learned Hand held that a patent
for adrenaline was valid because the adrenaline had
been isolated from nature.43 Specifically, the inventor
had made it available for any use by removing it from
other gland tissue in which it was found, thereby
transforming it for every practical purpose into a new
thing, commercially and therapeutically.44
Such decisions paved the way for the
patentability of biological products in their isolated
and purified form, a view that garnered further support
from the Court of Customs and Patent Appeals in
Application of Bergstrom.45 In that case, the court held
that two chemical entities of the prostaglandin family
extracted from prostate glands were patentable because
the compounds were not naturally occurring in their
purified form.46 The court asserted that pure materials
differ from impure materials by definition,47 and if
impure materials are the only ones existing and available,
consequently, the pure materials are new with respect to
the impure materials.48
Accordingly, courts have implicitly recognized
the patent-eligibility of purified and isolated DNA
molecules. In Amgen, Inc. v. Chugai Pharmaceuticals
Co.,49 the district court accepted the defendant’s assertion
that the claimed invention was a purified and isolated
DNA sequence encoding human erythropoietin, i.e.
the cloned gene rather than the sequence listing per se.50
Therefore, the claim was not directed towards a sequence
that would be “a nonpatentable natural phenomenon
‘free to all men and reserved exclusively to none.’”51 The
41. Id.
42. 189 F. 95 (C.C.S.D.N.Y. 1911).
43. Id. at 103.
44. Id.
45. 427 F.2d 1394 (C.C.P.A. 1970).
46. Id. at 1401-02.
47. Id. at 1401 n. 10 (“Webster’s . . . defines ‘pure’ as ‘Separate
from all heterogeneous or extraneous matter; free from mixture
or combination. . . .”) (quoting Webster’s New International
Dictionary, (2d ed. 1954)).
48. Id. at 1402.
49. No. 87-2617-Y, 1989 WL 169006, 13 U.S.P.Q.2d 1737
(D. Mass. Dec. 11, 1989) aff’d in part, vacated in part, 927 F.2d
1200, 1219 (Fed. Cir. 1991).
50. Id. at *32, 13 U.S.P.Q.2d at 1759.
51. Id. (quoting Diamond v. Chakrabarty, 447 U.S. 303, 309
(1980)).
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Federal Circuit accepted the district court’s construction
of the claim, specifying the subject matter as “the novel
purified and isolated sequence which codes for EPO.”52
Though the Supreme Court has not directly
addressed the issue of purified and isolated gene
sequences in the context of patent eligibility, an
affirmative decision would be in accord with its previous
decisions. With regard to biological products, the
Court in Diamond held that a bacterium genetically
engineered to carry multiple oil-degrading plasmids fell
within the ambit of patentable subject matter.53 The
Court concluded that the claimed microorganism was
a “nonnaturally occurring manufacture or composition
of matter” having “markedly different characteristics
from any found in nature,” contrasting it with “a new
mineral discovered in the earth or a new plant found
in the wild.”54 This holding has been interpreted by
at least one commentator to mean that natural things
left unaltered by human intervention are unpatentable
products of nature, while some natural things may be
so transformed by man that they cease to be products
of nature.55 Thus, the crucial question before the Court
in the instant appeal will be whether purification and
isolation of a genetic sequence results in a nonnaturally
occurring composition of matter with characteristics
markedly different from those of DNA in its natural
state sufficient to render it patentable subject matter.
2. Current Position of the USPTO
The USPTO has granted 4270 patents
containing claims directed to about 4382 human genes.56
In promulgating its Utility Examination Guidelines, the
USPTO responded to a number of comments received
regarding the patent-eligibility of human genes.57
Many such comments opined that a gene is not a new
composition of matter because it exists in nature, and
consequently, an inventor who isolates a gene does not
actually invent or discover a patentable composition.58
52. Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200,
1206 (Fed. Cir. 1991) (placing emphasis upon the terms “purified
and isolated”), see also In re Kubin, 561 F.3d 1351, 1352 (Fed.
Cir. 2009) (noting that “[t]his case presents a claim to a classic
biotechnology invention—the isolation and sequencing of a human
gene that encodes a particular domain of a protein”).
53. Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980).
54. Id. at 309-10.
55. Richard S. Gipstein, Note, The Isolation and Purification
Exception to the General Unpatentability of Products of Nature, 4
Colum. Sci. & Tech. L. Rev. 1, 3-4 (2003).
56. Jensen & Murray, supra note 2, at 239.
57. See Utility Examination Guidelines, 66 Fed. Reg.
1092, 1092 (Jan. 5, 2001) .
58. Id. at 1093.
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In response, the USPTO asserted that “a patent claim
directed to an isolated and purified DNA molecule
could cover a gene excised from a natural chromosome
or a synthesized DNA molecule.”59 Relying on ParkeDavis and In re Bergstrom, the USPTO emphasized
that a molecule having the same sequence as a naturally
occurring gene is patent-eligible because (1) an excised
gene is patent-eligible as a composition of matter because
that DNA molecule does not occur in that isolated form
in nature or (2) a synthetic DNA preparation is patenteligible because its purified state is different from the
naturally occurring compound.60
3. The District Court’s Decision in Myriad
Myriad holds, through assignment or exclusive
license, several U.S. patents on the isolated DNA
molecules relating to the BRCA1/2 sequences.61 Myriad
did not enforce its patents against academic research
institutions,62 but regularly sought enforcement against
both research institutions and commercial entities
providing commercial diagnostic testing through ceaseand-desist letters63 and litigation.64 At least nine clinical
diagnostic laboratories ceased BRCA1/2 testing due
to Myriad’s patent holdings.65 Myriad’s enforcement
actions precipitated AMP’s request for declaratory
judgment that Myriad’s patents on human BRCA1/2 are
invalid under 35 U.S.C. § 101 and are unconstitutional
because the granting of human gene patents by the
USPTO violates Article I, section 8, clause 8 and the
First Amendment of the Constitution.66
The claims addressed by the lawsuit fall into
two main categories: composition claims and method
(process) claims.67 The composition claims are directed
to isolated and purified DNA molecules that encode
either normal (wild-type) or mutant forms of BRCA1/2

59. Id. (emphasis added).
60. Id.
61. AMP Complaint, supra note 3, at ¶ 31.
62. Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office, 669 F. Supp. 2d. 365, 379 (S.D.N.Y. 2009) (referencing
letter to National Cancer Institute investigator assuring her that
Myriad would not interfere with her research activities).
63. See id. at 378–379 (discussing letters sent to the
University of Pennsylvania, Georgetown, and Yale).
64. See id (discussing the litigation it was involved in with
Oncormed and the University of Pennsylvania).
65. Id. at 380; Mildred K. Cho, et al., Effects of Patents and
License on the Provision of Genetic Testing Services, 5 J. Molecular
Diagnostics 3, Table 2 (2003).
66. AMP Complaint, supra note 3., at ¶ 102.
67. See Ass’n for Molecular Pathology v. U.S. Patent &
Trademark Office, 702 F. Supp. 2d 181, 212 (S.D.N.Y. 2010).

proteins.68 A representative composition claim is claim
one of U.S. Patent 5,747,282, which reads, “[a]n isolated
DNA coding for a BRCA1 polypeptide, said polypeptide
having the [following] amino acid sequence.”69 The
method claims are directed to diagnostic methods for
assessing a patient’s predisposition to the development
of breast and ovarian cancer using such isolated DNA
molecules as identified in the composition claims. A
representative method claim is claim twenty of U.S.
Patent 5,753,441, which reads:
A method for detecting a germline
alteration in a BRCA1 gene, said
alteration selected from the group
consisting of the alterations set forth
in [the Tables] . . . which comprise[]
analyzing a sequence of the BRCA1
gene or BRCA1 RNA from a human
sample or analyzing the sequence
of BRCA1 CDNA [sic] made from
mRNA from said sample.70
Several pre-trial motions were submitted to the
court: 1) AMP moved for summary judgment, declaring
that Myriad’s patents were invalid;71 2) Myriad moved
for summary judgment to dismiss AMP’s complaint for
lack of subject-matter jurisdiction, characterizing the
suit as consisting of a mere policy disagreement rather
than a real controversy;72 and 3) the USPTO moved
for judgment on the pleadings under the doctrine of
constitutional avoidance.73 The court stayed AMP’s
68. Id. at 211-12.
69. U.S. Patent No. 5,747,282 col. 153 ll. 56–59 (filed June
7, 1995).
70. U.S. Patent No. 5,753,441 col. 157 ll. 11-17 (filed Jan. 5,
1996). Method claims will not be discussed in detail as these claims
are beyond the scope of this paper.
71. Plaintiff’s Memorandum of Law in Support of Motion
for Summary Judgment, Ass’n for Molecular Pathology v. U.S.
Patent & Trademark Office, No. 09 Civ. 4515, 2009 WL 3269113
(S.D.N.Y. Aug. 26, 2009).
72. Memorandum of Law in Support of Defendant’s Motion
to Dismiss, Ass’n for Molecular Pathology v. U.S. Patent &
Trademark Office, 2009 WL 3269109 (S.D.N.Y. July 13, 2009)
(”This case is clearly a thinly veiled attempt to challenge the
validity of patents where, other than an overall policy disagreement
concerning the legitimacy of gene patents, the plaintiffs have no
actual dispute with the Defendants over patent infringement.”).
73. Memorandum of Law in Support of Defendant United
States Patent & Trademark Office’s Motion for Judgment on the
Pleadings and in Opposition to Plaintiff’s Motion for Summary
Judgment, Ass’n for Molecular Pathology v. U.S. Patent &
Trademark Office, 2009 WL 5785024 (S.D.N.Y. Dec. 24, 2009)
(“Because plaintiffs have not identified any way in which the
Constitution imposes limits on patents beyond those already
imposed by the patent laws, plaintiffs’ First Amendment claim
merges with their statutory claims, and should therefore be
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Motion for Summary Judgment pending its resolution
of Myriad’s motion to dismiss.74 On November 2, 2009,
the court denied Myriad’s motion to dismiss, stating that
“[t]he novel circumstances presented by this action . . .,
the absence of any remedy provided in the Patent Act,
and the important constitutional rights the Plaintiffs
seek to vindicate establish subject matter jurisdiction
over the Plaintiffs’ claim.”75 Ultimately, the USPTO’s
motion for judgment on the pleadings was granted,
dismissing the plaintiffs’ claims.76 Most significantly,
on March 29, 2010, the court granted AMP’s motion
for summary judgment, resulting in invalidation of the
challenged patent claims relating to Myriad’s BRCA1/2
composition and method claims.77
Though the Supreme Court has never made a
general statement that products of nature are patentineligible,78 the district court concluded that exclusion
of products of nature under 35 U.S.C. § 101 “reflects
the Supreme Court’s recognition that ‘phenomena
of nature . . . are not patentable.’”79 Thus, the court
delineated its sole task as determining “whether the
claimed invention . . . falls within the judicially created
‘products of nature’ exception.”80 Consistent with several
of the cases cited supra,81 the court acknowledged that a
change in a product of nature resulting in the creation
of a fundamentally new product would be eligible for
a patent.82 Using the restrictive language of Diamond
requiring that the product possess “markedly different
characteristics” to establish creation of a fundamentally
new product,83 the court concluded that isolated and
purified DNA does not possess markedly different
characteristics from native DNA.84

The European Patent Convention (“EPC”)
is a multilateral treaty that instituted the European
Patent Organization in order to provide an autonomous
legal system by which European patents are granted.
Practically, the grant of a European patent does
not provide a unitary right, but rather a “group” of
essentially independent patents granted on a single
application, nationally-enforceable and nationallyrevocable by Contracting states.85 The EPC provides a
legal framework for the granting of European patents
through a single, harmonized procedure before the
European Patent Office (“EPO”), a division of the
European Patent Organization.86
The EPC requires that patents be granted for
“any inventions which are susceptible of industrial
application.”87
Exceptions covering inventions
considered “discoveries, scientific theories, and
mathematical methods,” among others, are codified
within the treaty,88 rather than derived from case law
as in the United States. In addition, the European
Union may issue directives interpreting treaties such
as the EPC that require compliance by member States
through harmonization of their national laws to make
them consistent with the directive.89 Notably, the
European Union Biotech Directive interpreted the EPC
patentable subject matter exceptions narrowly, affirming
that isolated biological material is considered patentable
subject matter even if previously occurring in nature.90
The Directive further specifies that, if isolated from the
human body, “the sequence or partial sequence of a
gene” may constitute patentable subject matter, so long
as the industrial application of that sequence is disclosed

C. Patenting of Genes in Europe
1. European Patent Convention
dismissed.”).
74. Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office, 669 F. Supp. 2d. 365, 374 (S.D.N.Y. 2009).
75. Id. at 383.
76. Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office, 702 F. Supp. 2d 181, 238 (S.D.N.Y. 2010).
77. Id. at 232, 237.
78. Yoon, supra note 14, at 962 (citing Am. Fruit Growers,
Inc. v. Brodgex Co., 283 U.S. 1,11 (1931); Am. Wood-Paper Co v.
Fibre Disintegrating Co., 90 U.S. 566, 577-596 (1874); Cochrane
v. Badische Anilin & Soda Fabrik, 111 U.S. 293, 311 (1884)..
79. Ass’n for Molecular Pathology, 702 F. Supp. 2d at 218-19
(citing Gottschalk v. Benson, 409 U.S. 63, 67 (1972)).
80. Id. at 220.
81. See cases cited supra notes 36, 38, 43, 46, 50, 54.
82. Ass’n for Molecular Pathology, 702 F. Supp. 2d at 222.
83. Id. at 229 (citing Chakrabarty, 447 U.S. at 310 (1980)).
84. Id. at 232.
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85. Convention on the Grant of European Patents, art.
2(2), Oct. 5, 1973, 1065 U.N.T.S. 199 [hereinafter European
Patent Convention]; see also Case C-539/03, Roche Nederland
BV v. Frederick Primus, 2006 E.C.R. I-06535; Case C-4/03,
Gesellschaft für Antriebstechnik mbH & Co. KG v. Lamellen und
Kupplungsbau Beteiligungs KG, 2006 E.C.R. I-06509.
86. European Patent Convention, supra note 86, at art. 2(1).
87. Id. at art. 52 (emphasis added). Note the similarity in
breadth to the language of 35 U.S.C. § 101 requiring “any new and
useful process, machine, manufacture or composition of matter” for
patentability. (emphasis added)
88. Id. at art. 52(2). Other less germane exceptions include
aesthetic creations, schemes, rules and methods for performing
mental acts, playing games or doing business, programs for
computers, and presentations of information.
89. John Conley, European Court Issues a Gene Patent Ruling
Against Monsanto—A Myriad Connection?, Genomics Law Report
(July 28, 2010), http://www.genomicslawreport.com/index.
php/2010/07/28/european-court-issues-gene-patent-ruling-againstmonsanto-a-myriad-connection/.
90. Council Directive 98/44, art. 3, 1998 O.J. (L 213) 13-21
(EC).
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in the patent application.91
A European patent is subject to revocation
or narrowing by the EPO by either of two types of
post-grant procedure—an opposition procedure or a
limitation and revocation procedure.92 The opposition
procedure may initiated by any interested person from
the public who believes that the patent should not have
been granted.93 The opposition must be based on the
grounds set forth in Article 100 of the EPC,94 which
include that the invention lacks novelty, an inventive
step, or industrial application, and be received within
nine months of publication that the patent has been
granted.95 Once an opposition is filed, the opposition
division, consisting of three experienced examiners,
begins an investigation that includes examination of the
patent, invitation to the parties to file any observations,
and, typically, oral proceedings.96 The final outcome is
one of three possibilities: (1) revocation of the patent,
(2) maintenance of the patent, or (3) maintenance of the
patent in amended form.97 Subsequent to the decision
of the opposition division, the parties have the option to
appeal to the independent boards of appeal.98
2. European Patent Office’s Treatment of
Myriad’s Patents
The EPO granted four patents to Myriad
covering the BRCA1/2 genes and related diagnostic
methods,99 one of which claimed the isolated DNA
molecule encoding BRCA1.100 Opposition to the ‘902
patent was filed on August 28, 2002 by organizations
from eleven European countries101 on multiple grounds
91. Id. at art. 5.
92. European Patent Office, The Opposition Procedure,
http://www.epo.org/about-us/jobs/examiner/role/opposition.html
(last visited November 12, 2010).
93. Id.; see also Pins, supra note 16, at 401.
94. European Patent Convention, supra note 86, at art. 100.
95. The Opposition Procedure, supra note 94; See also
European Patent Convention, supra note 86, at art. 100(a).
96. The Opposition Procedure, supra note 94. Prior to the
oral proceedings, the patent holder can amend the description,
claims, and drawings.
97. Id.
98. Id.
99. EPO 0699754 (issued Jan. 10, 2001); EPO 0705902
(issued Nov. 28, 2001); EPO 0705903 (issued May 23, 2001); EPO
0785216 (issued Jan. 8, 2003).
100. EPO 0705902 (entitled 17q-linked breast and ovarian
cancer susceptibility gene)
101. Jordan Paradise, European Opposition to Exclusive Control
Over Predictive Breast Cancer Testing and the Inherent Implications
for U.S. Patent Law and Public Policy: A Case Study of the Myriad
Genetics’BRCA Patent Controversy, 59 Food & Drug L.J. 133, 138
(2004) [Hereinafter Opposition]. The eleven countries are Austria,
Belgium, Czech Republic, Denmark, Finland, Germany, Greece,

including lack of novelty, inventive step, and/or industrial
application.102 As for lack of novelty, Myriad claimed a
priority date to a patent application filed in the U.S. in
1994103 in which the BRCA1 sequence listing contained
ten errors ultimately requiring amendment on March 24,
1995 to reflect the correct sequence.104 During that time,
the molecule encoding BRCA1 was isolated by other
researchers and its sequence placed in scientific databases
and numerous articles in the public domain.105 Thus,
the challengers contended that the incorrect sequence in
the 1994 application could not overcome the absolute
novelty bar of the European patent system.106 With
regard to lack of inventive step, previous work of the
Breast Cancer Linkage Consortium had narrowed down
the region of the chromosome containing the BRCA1
gene considerably, so much so that one researcher felt
that it was only a matter of luck as to which individual
researcher would find it.107 In connection with lack
of industrial application, the challengers focused on
Article 52(4) of the EPC, which states that “diagnostic
methods practiced on the human . . . body shall not be
regarded as inventions which are susceptible of industrial
application.”108 Though the claim was directed towards
the isolated DNA molecule, the only use of that molecule
supported by the specification fell within the context of
a diagnostic method.
The opposition division failed to reach any
conclusions regarding the assertions of the challengers
regarding patentable subject matter, but instead
determined that Myriad improperly extended the
subject matter by amendment of claims after issuance
of the patent in violation of Article 123(2).109 As a
result, the patent was severely limited by invalidation of
claims directed towards the isolated BRCA1 molecule;
diagnostic methods; BRCA1 protein; conceivable
Italy, the Netherlands, Switzerland, and the United Kingdom.
102. Id.
103. Id. at 142.
104. Maurice Cassier, The Opposition Against the Patent of
Myriad Genetics and Their Total or Partial Revocation in Europe:
Early Conclusions, 21(6) Médicine Sciences (2005), available at
http://www.edk.fr/reserve/revues/ms_papier/e-docs/00/00/07/91/
document_article.md (translated by Google).
105. Opposition, supra note 102, at 142.
106. Id.
107. Id. at 143.
108. European Patent Convention, supra note 86, at Art.
52(4); Opposition, supra note 102, at 144.
109. European Patent Convention, supra note 86, at Art.
123(2); Jordan K. Paradise, Lessons from the European Union: The
Need for a Post-Grant Mechanism for Third-Party Challenge to
U.S. Patents, 7 Minn. J.L. Sci. & Tech. 315, 320-321 (2006)
[Hereinafter Lessons].
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therapeutic applications in gene therapy, drug screening,
and transgenic animals; and diagnostic kits.110 After the
opposition division’s decision, the new patent issued on
June 8, 2008, with only three claims directed towards
a BRCA1 DNA probe and a vector coding for said
probe.111 It appears that the EPO tacitly recognized the
validity of the challengers’ policy arguments in crafting
its decision but specifically sought to avoid making any
conclusions that might call into question the validity of
European patents on isolated DNA molecules.
3. Recent Developments in European Case
Law
Monsanto Technology LLC v. Cefetra B.V.112
is the first and only national court referral to the
European Court of Justice seeking an interpretation of
the EU Biotech Directive. Monsanto holds a European
patent claiming modified soybean DNA molecules that
confer the plant immunity to certain herbicides, also
manufactured by Monsanto.113 Cefetra, in an attempt
to take advantage of Monsanto’s lack of an Argentinean
patent covering the technology, imported soy meal
containing “dead” versions of the subject DNA sequences
into the Netherlands.114 Monsanto sued Cefetra in a
Dutch court for violation of national patent law, which,
similarly to that of the U.S., conveys an exclusive right
on the patent holder to exclude others from importing
the patented product.115
Cefetra asserted that the EU Biotech Directive
supersedes Dutch patent law. Specifically, Article 9
provides that protection extends to “all material . . . in
which the [patented] product is incorporated and in
which the genetic information is contained and performs
its function.”116 The Dutch court referred to the European
Court of Justice the question of whether absolute
protection of a DNA sequence, as such, is permissible
under the Directive despite the fact that the sequence
did not express its function at the time of importation.117
The European Court of Justice determined that such
110. Lessons, supra note 110, at 321.
111. Eur. Patent No. 0705902 (filed on Aug. 11, 1995).
112. Case C-428/08, Monsanto Tech., LLC v. Cefetra B.V.,
2010, http://curia.europa.eu/jcms/jcms/j_6/ (write case number
in “Case no” box; then click “Search”; choose the “2010-07-06
Judgment”).
113. Id.; Conley, supra note 90.
114. Id.
115. Id.; Rijksoctrooiwet [Law on Patents] art. 53 (Neth).
116. Council and Parliament Directive 98/44, art. 9, 1998
O.J. (L 213) (EC) available at http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=CELEX:31998L0044:EN:HTML.
117. Case C-428/08, Monsanto Tech., LLC v. Cefetra B.V.,
2010; Conley, supra note 90.
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protection provided by Dutch patent law violated Article
9 of the Directive.118 The court stated that “a mere DNA
sequence without indication of a function does not
contain any technical information and is therefore not a
patentable invention.119
Though the court’s ruling does not preclude
the patenting of genes, it appears to preclude absolute
protection of an isolated DNA molecule per se. Notably,
the court’s language emphasizing a DNA molecule’s
performance of function bears an interesting connection
to that of the district court in Myriad—it is not the
chemistry of the DNA sequence that is important, but
rather the function (i.e., information-delivering) of that
sequence.120 Because this decision was held to apply
retroactively, it remains to be seen what effect it will have
on gene patents such as those held by Myriad. Arguably,
under a more liberal view, the isolated DNA molecules
generated in the course of sequencing are not capable
of performing their function, making those molecules
ineligible for patent coverage in the European Union in
the diagnostic context.121
III. Arguments Surrounding the Gene Patenting
Debate
Parties on both sides of the gene patenting
debate have presented a number of valid arguments to
support their position. Opponents of gene patenting
assert that gene patents impede access to genetic testing,
hinder attempts to increase the quality of genetic testing,
and create barriers to basic research on certain genetic
mutations underlying development of disease. On the
other hand, proponents argue that isolated and purified
DNA is patentable subject matter, regardless of the
policy arguments against gene patenting, and that gene
patents stimulate investment in development of genetic
testing and further basic research related to the genetic
mutations that are the subject of such testing. In the
end, because isolated and purified DNA is patentable
subject matter and patents on genetic testing are crucial
for obtaining much-needed research dollars, the Court
of the Appeals for the Federal Circuit should overturn
the district court’s decision in Myriad.
118. Id.
119. Case C-428/08, Monsanto Tech., LLC v. Cefetra B.V.,
2010 (citing Counsel Directive, supra note 91 at Recital 23).
120. Conley, supra note 90.
121. Chris Holman, Monsanto v. Cefetra: EU Court of
Justice Limits Scope of Patent Protection Available to Gene Sequences,
Holman’s Biotech IP Blog, http://holmansbiotechipblog.
blogspot.com/2010/07/monsanto-v-cefetra-eu-court-of-justice.
html, (last visited Nov. 18, 2010).
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A. The Arguments Against Gene Patenting122
1.

Gene Patents Impede Access to Patient
Testing

As both the plaintiffs and the Secretary’s
Advisory Committee on Genetics, Health, and Society
(“SACGHS”) have recognized, the issue of limited access
typically arises in the context of a sole service provider.123
The basis for this argument lies in the assumption that
patents associated with genetic tests limit access by
raising prices above what would exist in the competitive
market.124 As a result many insurance carriers will not
cover testing, requiring patients to pay for the test outof-pocket.125 Though the test remains available to such
patients for such a premium, many patients, such as
those covered under state-run Medicaid programs, may
be forced to forego testing because they cannot afford
it.126 However, at least one case study demonstrated
that the per-unit price of the BRCA test is actually
comparable to a similar colon-cancer test for which the
patents have been nonexclusively licensed.127 In fact, the
SACGHS concluded there is no evidence that patents
have consistently led to higher prices for genetic tests.128
Viewing this issue from another perspective,
lack of patient access results from insurance industry
practices, rather than from patent exclusivity. As a
predictive genetic test, the BRCA test provides only a
general estimate of patients’ chances of developing breast
cancer, as it fails to take into account the influence of
other mutations and environmental factors, meaning
many women who test positive will never develop
breast cancer.129 Such technological limitations may
lead an insurance carrier to allocate its resources to
forms of testing that provide more concrete information
to patients. Indeed, there are a number of diagnostic
tests currently available that would provide beneficial
medical information to patients, whether in the context
122. See supra Section II(B)(3).
123. AMP Complaint, supra note 3, at ¶¶ 84–95; see also
Office of Biotechnology Activities, Report of the Secretary’s
Advisory Committee on Genetics, Health, and Society, Gene
Patents and Licensing Practices and Their Impact on Patient Access
to Genetic Tests 39-45 (Dep’t of Health & Human Services, Apr.
2010) [hereinafter SACGHS], available at http://oba.od.nih.
gov/oba/SACGHS/reports/SACGHS_patents_report_2010.pdf
(collecting case studies examining limitations on clinical and patient
access imposed by gene patents).
124. SACGHS, supra note 124, at 38.
125. Id. at 3.
126. Id.
127. Id. at 38.
128. Id. at 39.
129. Opposition, supra note 102, at 147.

of a sole provider or not, that insurance companies do
not cover.130 In addition, the financial gain to service
providers resulting from increased market size drives
active negotiation with payers in order to increase patient
pools, which in turn increases access, as evidenced by
Myriad’s reduction of the number of self-pay patients to
a single-digit percentage of its client base.131
2. Gene Patents Result in Decreased Quality
of Genetic Testing
It has been asserted that gene patents result in
decreased quality of genetic testing in two ways. First,
the quality of the actual diagnostic test may remain
stagnant, as market exclusivity fails to push service
providers to improve testing. For example, one French
study found that Myriad’s BRCA testing procedure failed
to detect ten to twenty percent of mutations.132 Some
commentators suggest that increased competition results
in improved testing regardless of whether available tests
are of high quality and subject to excellent quality control
procedures.133 On the other hand, there are several
technical advantages to centralizing genetic testing,
including the consistency that results from running
all tests on the same equipment using standardized
protocols and reagents and the ease of maintaining
regulatory oversight.134
Second, in the sole provider context,
confirmatory testing from an independent laboratory
remains unavailable.135 Therefore, it is difficult to
assess whether concerns about testing quality are wellfounded.136 Further, patients who receive inconclusive
test results lack additional options for determining their
predisposition to the development of disease. However,
Myriad has never received a single request from a
patient or healthcare provider to conduct a second
test at another lab.137 At least in the case of Myriad,
130. See generally SACGHS, supra note 124 (discussing
insurance carriers’ refusal to cover genetic testing for long-QT
syndrome, hearing loss, and spinocerebellar ataxia).
131. R. Cook-Deegan et al., Impact of patents and licensing
practices on access to genetic testing for inherited susceptibility to cancer:
comparing breast and ovarian cancers to colon cancers, 12 Genetics
in Medicine S30 (2010) (noting that Myriad’s testing is presently
covered by over 300 providers).
132. Steve Benowitz, French Challenge to BRCA1 Patent
Underlies European Discontent, 94 J. Nat’l. Cancer. Inst. 80
(2002).
133. SACGHS, supra note 124, at 47.
134. Id. at 47-48.
135. Id. at 3.
136. Id. at 46.
137. Defendants’ Memorandum of Law (1) in Support
of Their Motion for Summary Judgment and (2) in Opposition
to Plaintiffs’ Motion for Summary Judgment, Association for
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such quality concerns, in addition to recent scientific
developments, led the company to develop a second,
more robust test (the BART test), which is offered at no
cost when indicated.138
3. Gene Patents Create Barriers to Research
A common argument against the patenting of
isolated human DNA molecules is that such patents
impede research. In the instant case, the plaintiffs
allege that several scientists, due to potential liability for
their research activities, discontinued their research on
BRCA genes after Myriad secured its patents.139 Though
Myriad is not currently targeting non-commercial
researchers with its enforcement activities,140 there is no
exemption for these researchers, meaning that it would
be possible for Myriad to seek an injunction or institute
a patent infringement action against these researchers.
However, there is little evidence that gene patents held
by Myriad or any other entity have a negative impact
on basic or clinical research. For example, an empirical
study conducted at the University of Illinois examining
125 academic researchers demonstrated little to no
negative impact on research productivity.141 Another
study by the German government found that DNA
patents created no barrier to entry into fields of research
where isolated DNAs had been patented.142 Though
the prospect of receiving a patent is “not the major force
motivating scientists,” that is not a justifiable reason to
preclude genes as patentable subject matter, as patents
are important for commercialization of genetic tests.143
There is one valid argument that pervades the
issue of gene patents as an impediment to research—
there are possible negative effects on the future of
genetic testing due to its dependence on the growing
capacity to analyze multiple genes simultaneously.144
Molecular Pathology v. U.S. Patent & Trademark Office, No. 09
Civ. 4515, 2009 WL 5785008, at 49 (S.D.N.Y. Dec. 23, 2009)
[hereinafter Myriad’s Memo].
138. Myriad Introduces Enhanced BRACAnalysis Test for
Exceptionally High-Risk Cancer Patients (Aug. 1, 2006), http://
investor.myriad.com/releasedetail.cfm?ReleaseID=325803. An
example of such an indication would be inconclusive BRCA1 test
results.
139. Plaintiffs’ Rule 56.1 Statement of Material Facts at 3-5,
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office,
09 Civ. 4515 (S.D.N.Y. Aug. 26, 2009) [hereinafter Plaintiff’s
Statement].
140. Association for Molecular Pathology v. U.S. Patent &
Trademark Office, 669 F. Supp. 2d. 365, 379 (S.D.N.Y. Nov. 2,
2009).
141. Myriad’s Memo, supra note 136, at 45.
142. Id.
143. SACGHS, supra note 124, at 1-2.
144. Id. at 3.
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Because approximately twenty percent of genes have
been patented, development of multiplex tests and
parallel sequencing will be dependent on acquisition
of rights to multiple gene patents.145 Similarly, wholegenome sequencing would require acquisition of
rights to most, if not all, existing gene patents.146 The
cumulative costs of multiple licenses, the associated
costs of negotiations, and the right of a patent holder
to refuse to license his invention could prevent such
products from ever reaching the market.147
B. The Arguments for Gene Patenting
1. Purified and Isolated DNA Is Patentable
Subject Matter
From the beginning, the district court
appeared to view Myriad’s assertion of the isolation and
purification of DNA as transforming it into something
distinctly different in character with hostility, framing
such practice as a ‘“lawyer’s trick’ that circumvents the
prohibitions on the direct patenting of the DNA in
our bodies.”148 However, the district court’s assertion
that DNA’s unique characteristics differentiate it
from other chemical compounds149 seems to rely on
philosophical underpinnings in lieu of the scientific
analysis that provides the basis for this so-called
“lawyer’s trick.” Such philosophical justifications are
evident in the court’s statement that “DNA represents
the physical embodiment of biologic information” and
“DNA’s existence in isolated form alters neither this
fundamental quality of DNA as it exists in neither the
body nor the information it encodes.”150
The difference in the structural and functional
properties of isolated DNA when compared to those
of native DNA is critically important to the utility and
function of such claimed isolated DNA molecules.151
Native DNA is protected in the cell because it remains
surrounded by proteins and stably embedded in
chromosomes.152 Removal of associated cellular products
that facilitate packaging of the DNA into a chromosome
by isolation and purification fundamentally alters the
chemical structure of DNA. Such isolation renders
DNA molecules useful as physical probes and primers
for the identification of mutations in patients, thereby
145.
146.
147.
148.
149.
150.
151.
152.

Id.
Id.
Id.
Ass’n for Molecular Pathology, 702 F. Supp. 2d. at 185.
Id. at 228.
Id. at 185.
Myriad’s Memo, supra note 136, at 31.
Id at 30.
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allowing diagnosis of increased cancer susceptibility.153
Thus, the utility of such molecules is based on their ability
to target and interact with other DNA molecules, not
just the biological information contained within. Such
a function is dependent on an isolated DNA molecule’s
unique structure and chemistry,154 a structure and
chemistry that, importantly, is lacking in native DNA
molecules. As the court acknowledged, purified DNA
can be used as a tool for biotechnological applications
for which native DNA cannot be used.155
The uncontradicted scientific evidence
demonstrates that the isolation and purification of a
DNA molecule results in a new and useful composition
of matter in satisfaction of the requirements of 35 U.S.C.
§ 101 or an invention in the field of biotechnology in
satisfaction of Art. 52 of the EPC.156 This composition
of matter is not a law of nature, physical phenomenon, or
abstract idea, and so it does not fall within the exceptions
to § 101 established by case law.157 Similarly, it does not
fall within the EPC exceptions of a discovery, scientific
theory, or mathematical method.158 In determining
patent eligibility, isolated DNA molecules should be
treated no differently from other chemical compounds,
and the courts’ misplaced focus on the informationcontaining or information-delivering qualities of DNA
should not be used to justify such differential treatment.
2. Gene Patents Stimulate Investment
Though individual scientists may not be
motivated by the prospect of receiving a patent,
“meaningful gene-disease associations are confirmed
only if the initial discoveries are followed by large scale
replication and validation studies using multiple sample
sets, the costs of which are prohibitive for many research
groups.”159 Congress’s enactment of the Bayh-Dole
Act, which established a uniform policy among federal
agencies that academic institutions may patent inventions
arising from federally supported research and license
them to companies, is a direct acknowledgment of this

153. Id. at 32; See, e.g., U.S. Patent No. 5,693,473 (filed June
7, 1995).
154. Id. at 33.
155. 702 F. Supp.2d at 196.
156. 35 U.S.C. § 101; European Patent Convention, supra
note 86, at art. 52(1).
157. Diamond v. Chakrabarty, 447 U.S. at 309 (setting forth
the exceptions of laws of nature, physical phenomena, and abstract
ideas).
158. European Patent Convention, supra note 86, at art.
52(2).
159. SACGHS, supra note 123, at 23.

economic reality.160 It was premised on the belief that
absent exclusive patent rights from licenses, companies
will not invest resources to develop an invention into
a product because free-riders could copy the finished
product.161 Indeed, the strength of a company’s
intellectual property strategy and position is one of the
top three questions posed by investors.162 Thus, due
to the enormous sums of money required to discover,
develop, test, and approve genetic tests, notwithstanding
the time it takes to develop such tests, protection of the
related intellectual property is critical.163
Had it not been for the exclusive patent rights
it obtained regarding BRCA1/2 and the infusion of
capital that follows from such exclusivity, Myriad would
never have been created, and its BRCA1/2 tests would
never have been brought to the market, resulting in a
true barrier to patient access.164 For example, Eli Lilly
agreed to fund Myriad’s ongoing research efforts in
return for licensing privileges on diagnostic kits and
therapeutic products related to BRCA1.165 Similarly,
the prospect of gene patents has also been critical
to funding the development of genetic testing for
other diseases, including hereditary hemochromatosis
(Mercator Genetics), spinal diseases (Axial Biotech),
diseases that predominantly affect women (Juneau
Biosciences), spinal muscular atrophy (Claire Altman
Heine Foundation), and muscular dystrophy (Boston
Children’s Hospital).166 Though the federal government
remains the major funder of basic genetic research,167
private investment is necessary to translate basic research
from the lab bench to the patient’s bedside.
3. Gene Patents Stimulate Research
While it is evident that gene patents stimulate
the translational research needed to drive genetic testing
innovation from the lab to market, it is also clear that
gene patents stimulate basic research and discovery. Since
Myriad’s public disclosure of the BRCA1 gene in 1994
and BRCA2 gene in 1996, more than 18,000 scientists
160. Id. at 28.
161. Id. at 29.
162. Lisa A. Haile, IP Position Critical to Biotech Investment,
30(7) Wall Street BioBeat (April 1, 2010), http://www.
genengnews.com/gen-articles/ip-position-critical-to-biotechinvestment/3235/ One investment banker stated that “[w]e know
that if the IP position is not strong, it is unlikely that we will pursue
the opportunity further.” SACGHS, supra note 124, at 29.
163. Haile, supra note 16; SACGHS, supra note 124, at 29.
164. Myriad’s Memo, supra note 136, at 47.
165. SACGHS, supra note 124, at 23.
166. Id. at 24-26.
167. Id. at 25.
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have researched the genes, leading to the publication of
over 5,600 papers on BRCA1 and over 3,000 papers on
BRCA2.168 Interestingly, the individual plaintiffs and
their declarants in the instant case published forty-eight
peer-reviewed research papers on the BRCA1/2 genes
without any interference from Myriad.169 Apparently,
Myriad’s gene patents did nothing to impede their
research. Furthermore, Myriad has found it in its
own best interest to freely allow academic scientists to
conduct research studies on the BRCA1/2 genes, provide
direct assistance to such researchers, and publish and
actively disseminate its own research into the public
domain.170 Such stimulation of research is not unique
to the field of breast cancer. Human Genome Sciences
provided collaborators at Johns Hopkins University
access to the company’s proprietary database of DNA
sequences coding for receptor proteins, resulting in
the discovery of the MLH1 gene involved in colon
cancer.171 Though opponents of gene patenting may see
the biotech industry as capitalistic and self-serving, such
characteristics have resulted in an increased recognition
by biotech entities of the mutual benefits that flow from
collaborations with independent groups engaged in
basic research.

identifying and curing heritable disorders—a future that
will never happen without patent protection.

IV. Conclusion
The United States Court of Appeals for the
Federal Circuit should overturn the district court’s
decision in Myriad. First and foremost, isolated DNA
molecules fit within the definition of patentable subject
matter as defined by statute and developed through case
law. In addition, though there are valid arguments against
the patenting of such molecules, including the creation
of barriers to patient access, research, and improvement
of test quality, when weighed against arguments in
support this type of patenting, namely stimulation of
research and investment, it becomes clear that patenting
of isolated DNA molecules will have the most benefit to
the public as a whole. The intellectual property position
of biotech companies is one of the most important
factors potential investors consider, and, without
significant capital investment, research groups would
lack the considerable resources required to translate
these technologies into reliable, effective diagnostic
tests and treatments. The future of genetic medicine
looks promising, offering a number of innovations for
168. Myriad’s Memo, supra note 136, at 46.
169. Id.
170. Id at 47.
171. SACGHS, supra note 124, at 25; R. Cook-Deegan et al.,
supra note 130 at S29.

30

Spring 2011

